Journal of Clinical Oncology, Vol 20, Issue 13
(July), 2002: 2971-2979
© 2002 American Society for Clinical Oncology
Incipient Angiogenesis in Barretts Epithelium and Lymphangiogenesis in Barretts Adenocarcinoma
By Merja I. Auvinen,
Eero I.T. Sihvo,
Terhi Ruohtula,
Jukka T. Salminen,
Aki Koivistoinen,
Päivi Siivola,
Ragna Rönnholm,
Juhani O. Rämö,
Mathias Bergman,
Jarmo A. Salo
From the Cellular Signalling Group, Division of Biochemistry, Department of Biosciences, Viikki BioCenter, University of Helsinki; and Department of Cardiothoracic Surgery, Helsinki University Central Hospital; and Karyon Ltd, Viiki BioCenter, Helsinki, Finland.
Address reprint requests to: Merja Auvinen, PhD, Division of Biochemistry, Department of Biosciences, Viikinkaari 5D, P.O. Box 56, Viikki BioCenter, FIN-00014 University of Helsinki, Finland; email: merja.auvinen{at}astrazeneca.com
PURPOSE: Barretts esophagus (BE), a precancerous condition for Barretts adenocarcinoma, is classically characterized by flames of salmon-colored mucosa extending into normal pale esophageal mucosa. This flaming is thought to be a consequence of continuous erosis of mucosa caused by chronic reflux. Another characteristic feature of Barretts adenocarcinoma patients is the frequent development of lymph node metastases. We addressed whether onset of angiogenesis occurs in BE and if the lymphatic system might provide a route for Barretts adenocarcinoma cells to infiltrate regular lymph nodes.
PATIENTS AND METHODS: Fifteen surgically resected Barretts dysplasia or adenocarcinoma patients were included. Immunohistochemistry and a modified whole mount analysis were used.
RESULTS: The incipient angiogenesis originates from the pre-existing vascular network in the lamina propria and infiltrates Barretts epithelium, giving its ominous salmon-red color. Barretts epitheliumspecific goblet cells express vascular endothelial growth factor (VEGF)-A. The immature blood vessels show a relative absence of smooth muscle actin (SMA)-positive mural cells and express VEGF receptor (VEGFR)-2 and matrix metalloproteinase (MMP)-9 on their exterior. Coexpression of VEGF-C and its receptor VEGFR-3 on lymphatic vessels is demonstrated.
CONCLUSION: BE is strongly neovascularized not eroded. This novel concept of a molecular mechanism of the origin of BE might emphasize why precancerous BE can give rise to the more cancerous dysplasia and Barretts adenocarcinoma stages. In addition, adenocarcinoma cells induce lymphangiogenesis. The new lymphangiogenic vessels might provide a systemic route for adenocarcinoma cells to invade circulation and induce lymph node metastasis.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. S. Saad, J. L. Lindner, Y. Liu, and J. F. Silverman
Lymphangiogenesis in Esophageal Adenocarcinomas--Lymphatic Vessel Density as Prognostic Marker in Esophageal Adenocarcinoma
Am J Clin Pathol,
January 1, 2009;
131(1):
92 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Zhai, G. Liu, K. Asomaning, L. Su, M. H. Kulke, R. S. Heist, N. S. Nishioka, T. J. Lynch, J. C. Wain, X. Lin, et al.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk
Carcinogenesis,
December 1, 2008;
29(12):
2330 - 2334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson
Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy
Oncologist,
October 1, 2007;
12(10):
1165 - 1177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R C Fitzgerald
Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma.
Gut,
December 1, 2006;
55(12):
1810 - 1820.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M-A Brundler, J A Harrison, B de Saussure, M de Perrot, and M S Pepper
Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma
J. Clin. Pathol.,
February 1, 2006;
59(2):
191 - 195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist,
September 1, 2005;
10(8):
590 - 601.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Basson
Gut Mucosal Healing : Is the Science Relevant?
Am. J. Pathol.,
October 1, 2002;
161(4):
1101 - 1105.
[Full Text]
[PDF]
|
 |
|
|